Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMALTHEA phase IIa study of AZD7798 in moderate to severe Crohn's disease
CTR20250075Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of azd7798 in Crohn's disease, sponsored by AstraZeneca. Started Apr 2025; status: active.
02
Drugs
azd7798
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20250075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250075.